DEVELOPMENT OF MAPATUMUMAB, A FULLY HUMAN AGONISTIC MONOCLONAL ANTIBODY WHICH TARGETS AND ACTIVATES THE TRAIL-RECEPTOR-1

被引：0
|
作者：
Gallant, G. J. A. [1 ]
机构：
[1] Human Genome Sci, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [41] Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
    Sims, Gary P.
    Riggs, Jeffrey
    Hanna, Richard
    Rajan, Bhargavi
    Karnell, Jodi
    Zerrouki, Kamelia
    Sagar, Divya
    Vainshtein, Inna
    Farmer, Erika
    Liang, Meina
    Sanjuan, Miguel A.
    Kolbeck, Roland
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [42] Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor
    Sasaki-Iwaoka, Haruna
    Ohori, Makoto
    Imasato, Akira
    Taguchi, Katsunari
    Minoura, Kyoko
    Saito, Tetsu
    Kushima, Kiyoshi
    Imamura, Emiko
    Kubo, Satoshi
    Furukawa, Shigetada
    Morokata, Tatsuaki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 828 : 89 - 96
  • [43] Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor
    Schnitzer, T.
    Kuenkele, K. -P.
    Rebers, F.
    Van Vugt, M.
    Klein, C.
    Lanzendoerfer, M.
    Mundigl, O.
    Parren, P. W. H. I.
    van de Winkel, J. G. J.
    Schumacher, R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 66 - 67
  • [44] Monoclonal antibody to Shiga toxin 1, which blocks receptor binding and neutralizes cytotoxicity
    Nakao, H
    Kataoka, C
    Kiyokawa, N
    Fujimoto, J
    Yamasaki, S
    Takeda, T
    MICROBIOLOGY AND IMMUNOLOGY, 2002, 46 (11) : 777 - 780
  • [45] A MONOCLONAL-ANTIBODY AGAINST PERIPHERAL BENZODIAZEPINE RECEPTOR ACTIVATES THE HUMAN NEUTROPHIL NADPH-OXIDASE
    ZAVALA, F
    MASSON, A
    BRYS, L
    DEBAETSELIER, P
    DESCAMPSLATSCHA, B
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 176 (03) : 1577 - 1583
  • [46] Toll-like receptor 4 agonistic monoclonal antibody reverses new onset type 1 diabetes
    Bednar, Kyle
    Tsukamoto, Hiroki
    Wu, Yuehong
    Klmoto, Masao
    Ridgway, William
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [47] DEVELOPMENT OF A MONOCLONAL-ANTIBODY WHICH DISTINGUISHES HAMSTER GLUCOCEREBROSIDASE FROM RECOMBINANT HUMAN GLUCOCEREBROSIDASE
    KEYES, L
    RICHARDS, S
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A326 - A326
  • [48] Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (vol 25, pg 1390, 2007)
    Tolcher
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4701 - 4701
  • [49] Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody
    Seraj, Jabed
    Tsai, Max
    Seiberling, Michael
    Cutler, David
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3358S - 3358S
  • [50] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
    Sikic, B. I.
    Wakelee, H. A.
    von Mehren, M.
    Lewis, N.
    Calvert, A. H.
    Plummer, E. R.
    Fox, N. L.
    Howard, T.
    Jones, S. F.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345